A Phase 4 interventional study of Intravenous Nitroglycerin and IV Fluids in Contrast Induced Nephropathy, sponsored by Mt. Sinai Medical Center, Miami. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.
Sponsored by Mt. Sinai Medical Center, Miami · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Contrast-induced nephropathy (CIN) is a complication of percutaneous coronary angiography that occurs in about 10 to 20% of patients exposed to contrast media. Iodinated contrast is used during coronary angiography to see the coronary arteries. It has been shown that exposure to this agent may cause kidney injury. CIN usually goes away on its own but in some high risk patients it progresses into renal failure.
This research study offers a new possible option to prevent CIN. We propose that if intravenous nitroglycerin is given before the procedure it may lower the chances of developing contrast-induced nephropathy.
The Contrast Nephropathy and Nitrates trial (CoNaN) is a single center, randomized, 1 x 1 factorial clinical trial designed to test the effects of intravenous nitroglycerin infusion in renal function given prior to PCI.
Specific aims for this trial include:
To determine if intravenous nitroglycerin will decrease the incidence of contrast induced Nephropathy.
400 patients with a Mehran score of > 6 and a pre-procedural creatinine measurement will be enrolled. Following baseline assessments, patients will be randomly assigned to receive intravenous infusion nitroglycerine plus intravenous normal saline or normal saline only. Subjects will participate in this study from the time they sign consent (prior to angiographic procedure), until 48-72 hours post procedure.
Mt. Sinai Medical Center, Miami is the lead sponsor of 17 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV Nitroglycerin with IV Fluids
Drug: Intravenous Nitroglycerin · Drug: IV Fluids
IV Fluids
Drug: IV Fluids
Change in GFR
The primary endpoint for this trial will be to determine the change in glomerular filtration rate after exposure to contrast media. We will compare the change in GFR before and after PCI of the group that received intravenous nitroglycerin with the change in GFR before and after PCI of the group that did not receive intravenous nitroglycerin.
Time frame: Baseline and 48 to 72 hours post-PCI
| Milestone | Intravenous Nitroglycerin | Placebo |
|---|---|---|
| Started | 68 | 54 |
| Completed | 68 | 54 |
| Not completed | 0 | 0 |
The primary endpoint for this trial will be to determine the change in glomerular filtration rate after exposure to contrast media. We will compare the change in GFR before and after PCI of the group that received intravenous nitroglycerin with the change in GFR before and after PCI of the group that did not receive intravenous nitroglycerin.
| mL/min | Intravenous Nitroglycerin | Placebo |
|---|---|---|
| Change in GFR | 1.8 (-5.9 to 6.9) | -4.1 (-9.3 to 3) |
Collected over 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravenous Nitroglycerin | 0/68 (0%) | 0/68 (0%) | 4/68 (5.9%) |
| Placebo | 0/54 (0%) | 0/54 (0%) | 2/54 (3.7%) |
| Event | Intravenous Nitroglycerin | Placebo |
|---|---|---|
| HypotensionCardiac disorders | 4/68 | 2/54 |
122 patients consented for participation, met all inclusion/exclusion criteria and were analyzed in the intention-to-treat protocol.
| Age, Continuous(years) | Intravenous Nitroglycerin | Placebo | Total |
|---|---|---|---|
| Median | 77 (69.5 to 82) | 76 (68 to 85) | 76 (69 to 83) |
| Sex: Female, Male(Participants) | Intravenous Nitroglycerin | Placebo | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 52 | 38 | 90 |
| Race/Ethnicity, Customized(Participants) | Intravenous Nitroglycerin | Placebo | Total |
|---|---|---|---|
| Race/Ethnicity — White | 26 | 21 | 47 |
| Race/Ethnicity — Black | 5 | 3 | 8 |
| Race/Ethnicity — Asian | 2 | 2 | 4 |
| Race/Ethnicity — Hispanic | 34 | 27 | 61 |
| Race/Ethnicity — Unknown/not reported | 1 | 1 | 2 |
| Region of Enrollment(Participants) | Intravenous Nitroglycerin | Placebo | Total |
|---|---|---|---|
| United States | 68 | 54 | 122 |
| eGFR (Baseline)(mL/min) | Intravenous Nitroglycerin | Placebo | Total |
|---|---|---|---|
| Median | 58.3 (43.7 to 78.5) | 59.1 (48.5 to 77.6) | 58.6 (46.7 to 77.9) |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jun 2013, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitroglycerin
Mt. Sinai Medical Center, Miami